Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
56. |
ECCT/17/05/01 | Multicenter Study of the Accuracy of the BD MAXâ„¢MDR-TB Assay Multicenter Study of the Accuracy of the BD MAX™MDR-TB Assay for Detection of M. tuberculosis Complex and Mutations Associated with Resistance to Rifampin or Isoniazid |
Principal Investigator(s) 1. SAMUEL GURRION OUMA Site(s) in Kenya KENYA MEDICAL RESEARCH INSTITIUTE |
View |
57. |
ECCT/17/09/03 | A5354 Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses |
Principal Investigator(s) 1. Deborah Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Clinical Research Centre |
View |
58. |
ECCT/21/12/02 | The WHO ACTION Trial ACTION III: A multi-country, multi-centre, three-arm, parallel group, double-blind, placebo-controlled, randomized trial of two doses of antenatal corticosteroids for women with a high probability of birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes |
Principal Investigator(s) 1. Frederick Namenya Were 2. John Kinuthia 3. Zahida Parveen Qureshi Site(s) in Kenya 1. Coast General Teaching and Referral Hospital (Mombasa county) 2. Thika Level 5 Hospital (Kiambu county) 3. Nakuru Level 5 Hospital (Nakuru county) |
View |
59. |
ECCT/19/03/02 | PREVENT TD A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD) |
Principal Investigator(s) 1. Flynn Alexander Site(s) in Kenya Nyati Barracks, British Army Training Unit, Kenya |
View |
60. |
ECCT/17/08/04 | P1081 A PHASE IV RANDOMIZED TRIAL TO EVALUATE THE VIROLOGIC RESPONSE AND PHARMACOKINETICS OF TWO DIFFERENT POTENT REGIMENS IN HIV INFECTED WOMEN INITIATING TRIPLE ANTIRETROVIRAL REGIMENS BETWEEN 28 AND 36 WEEKS OF PREGNANCY FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION: NICHD P1081 |
Principal Investigator(s) 1. FREDRICK KIPYEGON SAWE Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Clinical Research Centre. |
View |